NASDAQ
16.01.26 | 22:00
14,060 US-Dollar
-6,14 % -0,920
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 2 | Investing.com Deutsch | ||
| Do | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| Mi | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| Mi | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 4 | Benzinga.com | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 11 | Investing.com | ||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals reports Preliminary Q4 results | 2 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | 116 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| 07.01. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating | 7 | Investing.com | ||
| 04.11.25 | Phathom Pharmaceuticals startet Phase-2-Studie mit VOQUEZNA bei eosinophiler Ösophagitis | 4 | Investing.com Deutsch | ||
| 30.10.25 | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | 1 | Seeking Alpha | ||
| 30.10.25 | Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim | 2 | Investing.com | ||
| 30.10.25 | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.10.25 | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,706 | -0,56 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range | -Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)- -ORLADEYO net revenue expected to be... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,305 | +0,52 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,899 | +1,71 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 4,789 | +0,55 % | Why ImmunityBio Stock Is Skyrocketing Again Today | ||
| CARDIFF ONCOLOGY | 2,560 | +2,61 % | Zweite Chance 2026: +100% Kursgewinn damals - kommt jetzt die Wiederholung? | ||
| ADAPTIMMUNE THERAPEUTICS | 0,017 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,326 | +2,46 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 20,500 | -2,38 % | Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| ZEVRA THERAPEUTICS | 7,600 | -1,94 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,880 | +7,49 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,065 | -2,18 % | Vir Biotechnology reports promising results for hepatitis delta therapy | ||
| DBV TECHNOLOGIES | 3,650 | -0,95 % | DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing | Châtillon, France, January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 87,50 | +1,16 % | PALVELLA THERAPEUTICS, INC. - 8-K, Current Report | ||
| MARKER THERAPEUTICS | 1,370 | -2,84 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 12,600 | 0,00 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results | Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively 1,318 patient start forms received... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,14 % bei einem Aktienkurs von 14,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.